GuideTechnology transfer

How a TTO licenses IP to a faculty or student startup: equity and deferred royalty

University startup license terms for Indian TTOs: NISP 2019 limits on royalty and equity, deferred payments, milestones and conflicts, with a worked deal.

By Sahil Sheikh, Regd. Patent & Trademark Agent, cRTTP 6 min read
Short answer

A university licenses IP to its own startup through a written licence that defers cash. Under the National Innovation and Startup Policy 2019, royalties should be no more than 4% of sale price, preferably 1 to 2%, or the institute can take 1% to 4% of shares instead. Upfront fees are usually small or deferred until funding or sales.

A startup founded by your own faculty or students is the easiest licensee to find and the hardest to price. It wants the technology, it has the inventors, and it has almost no cash. A TTO that asks for a normal upfront fee kills the company. A TTO that gives the IP away loses the institute's return and, later, its credibility with investors who expect clean paperwork.

The answer is a licence that defers cash and ties the institute's return to the startup's success. This guide sets out the national guidance in India, the main payment tools, the clauses that protect the institute and a worked deal.

What does national policy say?

The National Innovation and Startup Policy 2019, issued by the Ministry of Education's Innovation Cell (then the MHRD), is the main guidance for higher education institutions. On licensing to startups, it says:

Point NISP 2019
Licensing to startups Institutes will allow licensing of IPR from the institute to startups
Royalty No more than 4% of sale price, preferably 1 to 2%, unless pure software
Software A revenue share agreed between the institute and the company
Shares instead of royalty 1% to 4%
Incubator equity 2% to 9.5%, for services and facilities
Staff and faculty founders drawing full salary Institute can take no more than 20% of the shares the staff or faculty member takes, within the 9.5% limit
Technology source Only technologies originating in the same institute for faculty startups

NISP is guidance. Your institute's own IP and startup policy decides the actual terms, so read both. The faculty side of the same rules is covered in starting a company as a faculty member.

Which payment tools can a TTO use?

Tool How it works When it suits
Small upfront fee A token amount at signing Always, to make the licence a real commercial contract
Deferred fee A fixed sum due at a trigger: funding round, first sales or a date Startup expects to raise money soon
Running royalty A percentage of sales, within the NISP range Product sales are the main value
Equity Shares issued to the institute instead of, or with, royalty Value is in the company more than the product
Milestone payments Sums due on events such as regulatory approval Long development path, such as medical devices
Sublicence share A percentage of sublicensing income Startup may license onward instead of making the product

Most deals combine two or three. A common pattern is a small upfront fee, a deferred fee on the first funding round, and either a royalty or equity.

Royalty or equity for the institute

Royalty
Paid on sales, within 1 to 4%
Income starts only with sales
Simple to administer
vs
Equity
1% to 4% of shares under NISP
Value only on exit or dividends
Needs dilution and exit terms

Royalty suits products; equity suits companies investors will grow.

How should a deferred payment be written?

A deferred payment fails when its trigger is vague. Write:

  1. The amount, or a formula.
  2. The trigger: "within 60 days of the startup receiving cumulative equity investment of ₹1 crore", or "on the first anniversary of first commercial sale".
  3. A long-stop date, so the payment falls due even if the trigger never happens.
  4. Whether it converts to equity if the startup prefers.

Without a long-stop date, a startup that never raises a formal round never pays.

What protects the institute?

An exclusive licence to a startup carries more risk than one to an established company. Build in:

  • Diligence milestones: a prototype by a date, first sales by a date, funding raised by a date. See diligence obligations in exclusive licences.
  • The right to convert to non-exclusive or terminate if milestones are missed.
  • Patent cost terms: who pays prosecution and renewal fees, and from when.
  • Assignment limits: the licence cannot pass to an acquirer without consent, or passes only with a change-of-control payment.
  • Reporting: annual reports on development, funding and sales.
  • Conflict of interest: NISP asks institutes to develop a conflict-of-interest policy. Inventors who are founders should not negotiate for the institute.

Put the agreement in writing with all its terms; under section 68 of the Patents Act, a patent licence is valid only if it is in writing and duly executed. An MoU will not do; see MoU or licence agreement.

Licensing to an institute startup

1
Disclosure and IP checkInstitute owns the IP
2
Conflict checkFounders step out of negotiation
3
Term sheetFee, deferral, royalty or equity
4
Licence with milestonesWritten, all terms, signed
5
Annual reviewMilestones, reports, payments

What happens when the startup raises money or is sold?

Investors will read the licence before they invest, and an acquirer will read it before it buys. Three clauses decide whether the licence helps or blocks those deals.

Clause What to agree Why it matters
Change of control The licence continues on a sale, with notice to the institute, or a payment on change of control Acquirers need the licence to survive; the institute may want a share of the value
Sublicensing Whether the startup may sublicense, and the institute's share of sublicensing income A startup may license onward instead of making the product
Dilution If the institute holds licence equity, whether it is protected in early rounds or diluted with everyone else Small holdings shrink quickly without terms

Keep these terms simple. A licence with heavy restrictions on sale or funding can scare away the investors the startup needs, which hurts the institute too.

Investors also check that the startup holds clean rights: that the institute owns the IP, that every inventor assigned to the institute, and that the licence covers the product they are funding. A TTO that keeps these documents ready helps its startups close rounds faster.

A worked example

Illustration with invented figures and terms. An institute licenses a water sensor patent exclusively to a startup founded by two PhD graduates and their supervisor.

Term Amount
Upfront fee at signing ₹50,000
Deferred fee on first funding round of ₹1 crore or more, long-stop 3 years ₹5,00,000
Running royalty 2% of net sales
Equity instead of more royalty None; incubator holds 5% separately for services
Year three sales ₹2,50,00,000
Royalty in year three ₹5,00,000

If the startup raises its round in year two and reaches ₹2.5 crore of sales in year three, the institute receives ₹10.5 lakh over three years: ₹50,000 upfront, ₹5 lakh deferred and ₹5 lakh in royalty. If the startup stalls, the institute takes the licence back under the milestone clause and can offer the patent elsewhere. Inventor shares follow the institute's policy; see faculty royalty sharing.

Common mistakes

  • Charging a normal upfront fee that the startup cannot pay.
  • Deferred payments with no long-stop date.
  • Mixing up licence equity and incubator equity in one document.
  • Exclusive licences with no diligence milestones.
  • Letting a founder-inventor negotiate for the institute.

My view: a small royalty with clear milestones serves most institutes better than equity, because few institutes have the staff to manage shareholdings well. I am less certain for software startups, where NISP allows a revenue share and equity may fit investors better; take advice for each case.

For the patents behind these licences, Zernyx IPMS is an IP lifecycle management platform for universities and research institutions, to manage patents, filings and IP portfolios end to end.

Common questions

How much royalty can an Indian institute charge its own startup?

The National Innovation and Startup Policy 2019 says royalties would be no more than 4% of sale price, preferably 1 to 2%, unless the product is pure software, where a revenue share can be agreed. Individual institutes set their own policies within this guidance.

Can a university take equity instead of royalty?

Yes. NISP 2019 says that if the institute takes shares in the company, the shares will be 1% to 4%. Separately, an institute's incubator may take 2% to 9.5% equity in return for services and facilities. Keep the two clearly apart in the documents.

What is a deferred royalty or deferred fee?

A payment the startup owes but pays later, triggered by an event such as a funding round, first sales or a set date. It lets a cash-poor startup take a licence now while the institute keeps a fair price. The trigger and amount must be written into the licence.

Should a university give its startup an exclusive licence?

Often, because investors want exclusivity. Grant it for a defined field and territory, with diligence milestones the startup must meet, and the right to narrow or end exclusivity if it does not. That protects the institute if the startup stalls.

Sahil Sheikh
About the author

Sahil Sheikh, Regd. Patent & Trademark Agent, cRTTP

Chief IP & Technology Officer, Zernyx Innovations

Connect on LinkedIn

Manage every patent in one place.

Zernyx IPMS is an IP management system to manage patents, filings and IP portfolios end to end.

Explore Zernyx IPMS

Keep reading

Looking for something else?